and sales of consumer and industry-class high-performance general-purpose legged and humanoid robots, six-axis manipulators, and so on … At present, we have applied for more than 180 domestic ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

At the time, Musk said Tesla would start unsupervised FSD in Texas and California in 2025 for its Model 3 and Model Y EVs. However, the Cybercab and Robovan aren't expected to start production ...

More than a dozen humanoid robots, dressed in traditional Yangge costumes and holding red handkerchiefs, took the stage and performed in perfect sync with the dancers. On stage, the humanoid robot ...

Stock Market today: ICICI Bank, HDFC Bank and Axis Bank share prices gained up to 3% in the morning trade on Tuesday ahead of the RBI policy meeting next week and liquidity booster by the central ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics ... process on the overall design of the Company’s planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate ...

China will host the world's first half-marathon race between humans and robots. Dozens of humanoid robots are expected to join the 21km (13-mile) race in Beijing in April, according to local media.

The robot's 12-year-old inventor gazes back. "How would you describe yourself? Give me a five-word answer," Alex Rose tells his creation. AIRO, which stands for AI Robot, pauses and then ...

Cartesian Therapeutics, Inc. announced that it received FDA agreement on the design of its upcoming Phase 3 AURORA trial for Descartes-08, an mRNA cell therapy intended for treating myasthenia ...

3. Upgrades to intelligent motion control ... User-friendly automation, multi-axis robots and Cartesian robots Multi-axis robots with flexibility and multi-function [are] suitable for complicated ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ ... process on the overall design of the Company’s planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy ...